Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00332280 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | terminated | Phase 2 / Phase 3 | 67 | Auron Healthcare GmbHINDUSTRY | 2 | Mar 20, 2013 | clinicaltrials |
| NCT00676650 | Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy(SUN 1120) | terminated | Phase 3 | 873 | PfizerINDUSTRY | 22 | Mar 8, 2013 |
| clinicaltrials |
| NCT00014586 | Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer | terminated | Phase 3 | 110 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00626548 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer(ENTHUSE M0) | terminated | Phase 3 | 2,577 | AstraZenecaINDUSTRY | 39 | Sep 3, 2012 | clinicaltrials |
| NCT00450970 | Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)(SPERA) | terminated | Phase 3 | 344 | AgennixINDUSTRY | 1 | Aug 17, 2012 | clinicaltrials |
| NCT00388804 | External Beam Radiation Therapy (EBRT) With or Without Hormonal Therapy in Prostate Cancer | terminated | Phase 3 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 8, 2012 | clinicaltrials |
| NCT00127387 | Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia | terminated | Phase 2 / Phase 3 | 54 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 26, 2012 | clinicaltrials |
| NCT00294437 | ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases | terminated | Phase 3 | 376 | Central European Cooperative Oncology GroupOTHER | 16 | May 1, 2012 | clinicaltrials |
| NCT00911027 | SonoVue Guided Prostate Biopsy | terminated | Phase 3 | 282 | Bracco Diagnostics, IncINDUSTRY | 7 | Apr 25, 2012 | clinicaltrials |
| NCT00705822 | Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer(PROSTATA) | terminated | Phase 3 | 54 | SanofiINDUSTRY | 1 | Nov 30, 2010 | clinicaltrials |
| NCT00630799 | Efficacy and Safety Study of a New Leuprolide Acetate 17 mg Depot to Treat Prostate Cancer Patients | terminated | Phase 3 | 20 | GP-PharmINDUSTRY | 1 | Sep 9, 2010 | clinicaltrials |
| NCT00312442 | Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy | terminated | Phase 2 / Phase 3 | 16 | STEBA FranceINDUSTRY | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00391950 | Maintaining Bone Strength in Men With Prostate Cancer | terminated | Phase 3 | 300 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00089856 | GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | terminated | Phase 3 | 626 | Cell GenesysINDUSTRY | 8 | Nov 5, 2008 | clinicaltrials |
| NCT00133224 | Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients | terminated | Phase 3 | 408 | Cell GenesysINDUSTRY | 10 | Sep 23, 2008 | clinicaltrials |
| NCT00273338 | DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) | terminated | Phase 3 | 1,200 | NovaceaINDUSTRY | 9 | Nov 6, 2007 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2013source: clinicaltrials